A Curcumin Derivative That Inhibits Vinyl Carbamate-Induced Lung Carcinogenesis via Activation of the Nrf2 Protective Response

Antioxidants and Redox Signaling

Volumn 23, Issue 8, 2015, Pages 651-664

  Shen, Tao ^a,b   Jiang, Tao ^a   Long, Min ^c   Chen, Jun ^d   Ren, Dong Mei ^b   Wong, Pak Kin ^e   Chapman, Eli ^a   Zhou, Bo ^f   Zhang, Donna D ^a,g  

^a UNIVERSITY OF ARIZONA   (United States)

^b SHANDONG UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d WUHAN UNIVERSITY   (China)

^e University of Arizona   (United States)

^f LANZHOU UNIVERSITY   (China)

^g UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ARSENITE SODIUM; BIS[2 HYDROXYBENZYLIDENE]ACETONE; CARBAMIC ACID; CARBON; CURCUMIN; DRUG DERIVATIVE; GLUTATHIONE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VINYL CARBAMATE; VINYL DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENOUS ACID DERIVATIVE; BENZYL DERIVATIVE; BIS(2-HYDROXYBENZYLIDENE)ACETONE; NFE2L2 PROTEIN, HUMAN; SODIUM DERIVATIVE; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOGENESIS; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ACETONE; ANIMALS; ANTICARCINOGENIC AGENTS; ARSENITES; BENZYL COMPOUNDS; CARCINOGENESIS; CELL LINE, TUMOR; CURCUMIN; EPITHELIAL CELLS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; NF-E2-RELATED FACTOR 2; SODIUM COMPOUNDS; URETHANE;

EID: 84940922894     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6074     Document Type: Article

References (51)

1. Anand P, Kunnumakkara AB, Newman RA, and Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 4: 807-818, 2007.
2. Balogun E, Hoque M, Gong P, Killeen E, Green C, Foresti R, Alam J, and Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371: 887-895, 2003.
3. Byrd DM, Roegner ML, Griffiths JC, Lamm SH, Grumski KS, Wilson R, and Lai S. Carcinogenic risks of inorganic arsenic in perspective. Int Arch Occup Environ Health 68: 484-494, 1996.
4. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Jr. , and Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354-364, 2011.
5. Chen C, Chen C, Wu M, and Kuo T. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66: 888, 1992.
6. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
7. Ding W, Hudson LG, and Liu KJ. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol Cell Biochem 279: 105-112, 2005.
8. Dinkova-Kostova AT, Cory AH, Bozak RE, Hicks RJ, and Cory JG. Bis (2-hydroxybenzylidene) acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway. Cancer Lett 245: 341-349, 2007.
9. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99: 11908-11913, 2002.
10. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A 98: 3404-3409, 2001.
11. Du Y, Villeneuve NF, Wang X-J, Sun Z, Chen W, Li J, Lou H, Wong PK, and Zhang DD. Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect 116: 1154, 2008.
12. Farombi EO, Shrotriya S, Na H-K, Kim S-H, and Surh Y-J. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol 46: 1279-1287, 2008.
13. Garg R, Gupta S, and Maru GB. Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo [a] pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis 29: 1022-1032, 2008.
14. Goel A, Jhurani S, and Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 52: 1010-1030, 2008.
15. Gupta SC, Patchva S, and Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15: 195-218, 2013.
16. Hamaguchi T, Ono K, and Yamada M. REVIEW: curcumin and Alzheimer's disease. CNS Neurosci Ther 16: 285-297, 2010.
17. Hatcher H, Planalp R, Cho J, Torti F, and Torti S. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
18. Hayes JD and McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 21: 732-734, 2006.
19. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, and Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64: 6424-6431, 2004.
20. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, and Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: Possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 92: 33-38, 2003.
21. Jaramillo MC and Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27: 2179-2191, 2013.
22. Jeong W-S, Jun M, and Kong A-NT. Nrf2: A potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 8: 99-106, 2006.
23. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev 14: 141, 2009.
24. Kang ES, Woo IS, Kim HJ, Eun SY, Paek KS, Kim HJ, Chang KC, Lee JH, Lee HT, and Kim J-H. Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic Biol Med 43: 535-545, 2007.
25. Kensler TW and Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
26. Khor TO, Huang M-T, Prawan A, Liu Y, Hao X, Yu S, Cheung WKL, Chan JY, Reddy BS, and Yang CS. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1: 187-191, 2008.
27. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, and Aggarwal BB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125: 2187-2197, 2009.
28. Lau A, Whitman SA, Jaramillo MC, and Zhang DD. Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. J Biochem Mol Toxicol 27: 99-105, 2013.
29. Lee KW, Bode AM, and Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11: 211-218, 2011.
30. Magesh S, Chen Y, and Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 32: 687-726, 2012.
31. Massey TE, Devereux TR, Maronpot RR, Foley JF, and Anderson MW. High frequency of K-ras mutations in spontaneous and vinyl carbamate-induced lung tumors of relatively resistant B6CF1 (C57BL/6J x BALB/cJ) mice. Carcinogenesis 16: 1065-1069, 1995.
32. McNally SJ, Harrison EM, Ross JA, Garden OJ, and Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med 19: 165-172, 2007.
33. Mehta RG, Murillo G, Naithani R, and Peng X. Cancer chemoprevention by natural products: how far have we come? Pharm Res 27: 950-961, 2010.
34. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, and Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo [a] pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24: 461-467, 2003.
35. Satoh H, Moriguchi T, Takai J, Ebina M, and Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73: 4158-4168, 2013.
36. Shen G, Xu C, Hu R, Jain MR, Gopalkrishnan A, Nair S, Huang M-T, Chan JY, and Kong AN. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther 5: 39-51, 2006.
37. Shi H, Shi X, and Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 255: 67-78, 2004.
38. Sporn MB and Suh N. Chemoprevention: An essential approach to controlling cancer. Nat Rev Cancer 2: 537-543, 2002.
39. Srivastava RM, Singh S, Dubey SK, Misra K, and Khar A. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol 11: 331-341, 2011.
40. Tao S,Wang S,Moghaddam SJ, OoiA,Chapman E,Wong PK, and Zhang DD. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 74: 7430-7441, 2014.
41. Tao S, Zheng Y, Lau A, Jaramillo MC, Chau BT, Lantz RC, Wong PK, Wondrak GT, and Zhang DD. Tanshinone I activates the Nrf2-dependent antioxidant response and protects against As (III)-induced lung inflammation in vitro and in vivo. Antioxid Redox Signal 19: 1647-1661, 2013.
42. Tapia E, Soto V, Ortiz-Vega KM, Zarco-Márquez G,Molina-Jijón E, Cristóbal-Garc?á M, Santamar?á J, Garc?á-Niño WR, Correa F, and Zazueta C. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev 2012: 269039, 2012. DOI: 10. 1155/2012/269039.
43. Taylor RA and Leonard MC. Curcumin for inflammatory bowel disease: A review of human studies. Altern Med Rev 16: 152-156, 2011.
44. Thangapazham RL, Sharma A, and Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 8: E443-E449, 2006.
45. Tokar EJ, Benbrahim-Tallaa L, Ward JM, Lunn R, Sams RL, 2nd, and Waalkes MP. Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit Rev Toxicol 40: 912-927, 2010.
46. Wang XJ, Sun Z, Chen W, Eblin KE, Gandolfi JA, and Zhang DD. Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. Toxicol Appl Pharmacol 225: 206-213, 2007.
47. Wang X-J, Sun Z, Chen W, Li Y, Villeneuve NF, and Zhang DD. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol Appl Pharmacol 230: 383-389, 2008.
48. Wang X-J, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, and Wondrak GT. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008.
49. Xu C, Huang M-T, Shen G, Yuan X, Lin W, Khor TO, Conney AH, and Kong A-NT. Inhibition of 7, 12-dimethylbenz (a) anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 66: 8293-8296, 2006.
50. Yu X and Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat Res 591: 93-102, 2005.
51. Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23: 8137-8151, 2003.